Unlabeled Use:
Contraindicated in:
Use Cautiously in:
CV: arrhythmias, hypotension.
Derm: DRUG REACTION WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), ERYTHEMA MULTIFORME, rash, STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS, urticaria.
GI: diarrhea, CDAD, bitter or metallic taste, esophagitis, esophageal ulcer, nausea, vomiting.
Local: local irritation (topical products), phlebitis at IV site.
Neuro: dizziness, headache, vertigo.
Drug-Drug:
(Generic available)
Cleocin, Cleocin T, Clinda-Derm, Clindagel, Clindesse, Clindets, Xaciato
Spectrum:
Absorption: Well absorbed following PO/IM administration. Minimal absorption following topical/vaginal use.
Distribution: Widely distributed. Does not significantly cross blood-brain barrier. Crosses the placenta; enters breast milk.
Protein Binding: 94%.
Metabolism/Excretion: Mostly metabolized by the liver by the CYP3A4 isoenzyme.
Half-life: Neonates: 3.68.7 hr; Infants up to 1 yr: 3 hr; Children and adults: 23 hr.
(plasma concentrations)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO | rapid | 60 min | 68 hr |
IM | rapid | 13 hr | 68 hr |
IV | rapid | end of infusion | 68 hr |
NDC Code*